Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

8 Apr 2022

Abstract excerpt

Abstract Sequencing of cell-free DNA (cfDNA) in cancer patients’ plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection decreases at lower cfDNA tumor fractions, limiting utility at earlier stages of the disease. To test a novel strategy for detection of allelic imbalance, we developed a prostate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Molecular Biology Techniques and Applications
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35664542
DOI: 10.1093/narcan/zcac016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayPMID 35664542Read ↗

Technical and biological constraints on ctDNA-based genotyping.Semantic proximity Read ↗

A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancerSemantic proximity Read ↗

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.Semantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNASemantic proximity Read ↗

Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fractionSemantic proximity Read ↗

A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.Semantic proximity Read ↗

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate CancerSemantic proximity Read ↗

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Semantic proximity Read ↗

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Semantic proximity Read ↗

Clinical determinants for successful circulating tumor DNA analysis in prostate cancerSemantic proximity Read ↗

A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.